Martine A. Rothblatt, serving as both Chairperson and Chief Executive Officer of United Therapeutics Corp (NASDAQ:UTHR), finalized the sale of 9,500 shares of the company's common stock on June 16, 2026. The total value of these sales reached approximately $5.22 million. The execution of this transaction was conducted under the parameters of a pre-arranged 10b5-1 trading plan, a mechanism designed to facilitate trades in compliance with securities regulations.
The shares were sold at varying prices within a range of $544.58 to $555.20 per share. This activity occurs against a backdrop of strong recent performance for the stock, which has recorded an 89% return over the past year. As of the reporting date, United Therapeutics shares were trading at $551.47, supporting a market capitalization of $23.39 billion.
Parallel to the sales, Rothblatt acquired 9,500 shares of common stock through the exercise of stock options. These options were exercised at a price of $146.03 per share, resulting in an acquisition cost of approximately $1.39 million. This purchase was also integrated into the same 10b5-1 trading plan that was initially adopted on November 7, 2025. The plan is structured to remain active until one of two conditions is met: the exercise of all 1,734,410 stock options, which are set to expire on March 15, 2027, or the date December 31, 2026, whichever arrives first.
Following the completion of these transactions, Rothblatt's direct holdings in United Therapeutics common stock stand at 40,513 shares. Her broader ownership position includes indirect interests held through a spouse and family trusts, which total 628,215 shares. Additionally, she retains 21,910 stock options directly.
Market analysis indicates that United Therapeutics stock currently appears on lists of overvalued equities based on fair value calculations. For investors seeking comprehensive data, detailed research reports are available for UTHR and over 1,400 other US equities.
In recent corporate developments, United Therapeutics announced that its TETON-1 phase 3 study of nebulized Tyvaso in the treatment of idiopathic pulmonary fibrosis successfully met its primary endpoint. The results, published in the New England Journal of Medicine, demonstrated that Tyvaso preserved lung function and significantly reduced the risk of clinical worsening events.
Financially, the company reported first-quarter revenue of $781.5 million. This figure fell short of the consensus estimate of $797.4 million. Specifically, Tyvaso revenues reached $457.5 million, missing the expected $478.6 million. Net income was reported at $274.9 million, compared to the anticipated $320.5 million.
Following these earnings results, BTIG maintained a Neutral rating on United Therapeutics. In contrast, TD Cowen reiterated its Buy rating on the stock, setting a price target of $675.00. The company is also engaged in a partnership with Varda Space Industries to explore microgravity-based pharmaceutical processing for treating rare pulmonary diseases. This collaboration aims to leverage the effects of microgravity on therapeutic compounds to enhance drug stability and delivery.